BELKYRA® injection is a prescription medicine containing 10 mg/mL deoxycholic acid. It is used for the improvement in the appearance of moderate to severe convexity or fullness associated with fat below the jaws in adults.  Do not use in people allergic to this medicine, with infection at site of injection, pregnancy, and lactation.  Possible side effects include headaches, difficulty swallowing, nausea, skin tightness, hypertension, injection site bruising/pain/swelling/numbness/redness/tingling/hardness/itching /discolouration/formation of small areas of hardness/warmth and injection site nerve injury. BELKYRA® treatment is not funded on the New Zealand Pharmaceutical Schedule. You will need to pay for this medicine. Normal Doctors visit fees apply. BELKYRA® treatment should be administered only by trained medical professionals. Speak to your specialist about your own situation and about the benefits/risks of this procedure in appearance medicine. For further information, the Data Sheet and Consumer Medicines Information can be accessed at www.medsafe.govt.nz or ask your doctor. If you have any side effects or concerns speak to your doctor. Note: Results from BELKYRA® treatment usually last up to 4 years. Allergan New Zealand Limited, Auckland.

TEOSYAL RHA® 1, TEOSYAL  RHA® 2, TEOSYAL RHA® 3, TEOSYAL RHA® 4, TEOSYAL® PURESENSE REDENSITY 1, TEOSYAL® PURESENSE REDENSITY 2, TEOSYAL PURESENSE KISS ®, TEOSYAL® PURESENSE GLOBAL ACTION, TEOSYAL® PURESENSE DEEP LINES, TEOSYAL® PURESENSE ULTIMATE and TEOSYAL® PURESENSE ULTRA DEEP TEOSYAL KISS®, RHA KISS®, TEOSYAL® MESO,  TEOSYAL® GLOBAL ACTION, TEOSYAL® DEEP LINES, , TEOSYAL® ULTIMATE and TEOSYAL® ULTRA DEEP  are trademark of the firm TEOXANE SA. These products are gel that contains hyaluronic acid, and 0.3% by weight of lidocaine hydrochloride They are class III medical devices. Caution for people on blood thinning medicines. Local side effects: inflammatory reactions (redness, oedema, pain at the point of injection), haematomas, itching, temporary loss of sensitivity around the injected area, disorders of pigmentation in skin and hair, abscesses, indurations, nodules (possibly granulomas). General manifestations: immediate hypersensitivity up to anaphylactic shock, migration of the implant. Rare but serious adverse events associated with the intravascular injection of soft tissue fillers in the face have been reported and include temporary or permanent vision impairment or blindness, skin necrosis and stroke. Lasts 9 -12 months. Please consult your doctor pharmacist for more information. Please refer to instructions for use, local distributor. Healthcare Logistics, Auckland.

MINT MONO threads are smooth monofilament stimulating threads, pre-threaded onto a 29 Gauge needle. They are made from PDO (polydioxanone) Material which has been used in surgery as a suture material for over 30 years. These threads are placed in the superficial subcutaneous dermal layer of the skin.  They support the formation of new collagen and helps support skin firmness and elasticity.  MINT MONO threads are completely absorbed by the body in about 3-4 months after treatment.

MINT MONO threads are versatile and can be used in many areas across the face and body.  Treatment areas include Cheeks, Accordion Lines (Smile Lines), Perioral (Lip Lines), Marionettes, Nasolabial Folds, Jawline, and Neck.

Potential Risks and Complications:

 There are a number of possible side effects associated with MINT MONO. These side effects include but are not limited to:

• Bruising: patients should anticipate bruising with this treatment

• Redness: for several hours following treatment

• Pain and discomfort:  throughout the procedure and patients may experience some discomfort for several days afterwards as the threads settle

• Localised swelling can occur after the treatment; however, this should settle in 24 hours after the treatment

Distributed in New Zealand by Mondeal, 732 Forest Rd, Peakhurst NSW  2210

REJURAN is a dermal tissue reconstructive material, animal derived. REJURAN is an injectable gel which is intended for injection into the mid to deep dermis to promote tissue restoration and reconstruction, and improvement of physical appearance.

Administered by injecting the gel into the dermis using a thin gauge needle. The polynucleotide is hydrating to cause volumetric increases of tissues and make more favourable physiological conditions for the growth of cells in the skin.

REJURAN treatment is not funded on the New Zealand Pharmaceutical Schedule. You will need to pay for this medicine. Normal Doctors visit fees apply. REJURAN treatment should be administered only by trained medical professionals. Speak to your doctor about your own situation and about the benefits/risks of this procedure in appearance medicine. For further information, the Data Sheet and Consumer Medicines Information can be accessed at www.medsafe.govt.nz or ask your doctor. If you have any side effects or concerns speak to your doctor.

BTL EMSELLA is designed to provide deep tissue electromagnetic stimulation and intended to provide pelvic floor muscle strengthening for treatment of genitourinary system incontinence, urinary incontinence after radical prostatectomy, female sexual dysfunction, erectile dysfunction and pelvic pain syndrome in male and female patients. All medicines, medical devices and treatments carry benefits and risks. Individual results may vary. For details on precautions & side effects consult your healthcare professional. Always follow any instructions provided in terms of treatment aftercare. ⁠ Supplier BTL Medical Technologies Pty Ltd, Auckland. ⁠PP3704

BTL EMFACE is designed to provide simultaneous application of synchronized radiofrequency and high intensity facial electrical stimulation technology to treat multiple facial layers simultaneously. EMFACE is intended for aesthetic procedures such as facial rejuvenation and contouring by wrinkle reduction and skin laxity improvement and by means of toning and lifting of muscles and skin. All medicines, medical devices and treatments carry benefits and risks. Individual results may vary. For details on precautions & side effects consult your healthcare professional. Always follow any instructions provided in terms of treatment aftercare. ⁠ Supplier BTL Medical Technologies Pty Ltd, Auckland.

BTL EMSCULPT is designed to provide a combination of bipolar radiofrequency and high intensity electro magnetic energy for muscle toning. We also recommend regular physical activity and following a well-balanced diet. All medicines, medical devices and treatments carry benefits and risks. Individual results may vary. For details on precautions & side effects consult your healthcare professional. Always follow any instructions provided in terms of treatment aftercare. ⁠ Supplier BTL Medical Technologies Pty Ltd, Auckland.

STYLAGE® Lips Plus (20mg/mL) IPN-Like Cross-linked Hyaluronic acid gel of non-animal origin with Mannitol and 0.3% Lidocaine is classified as medical devices Class III specially indicated for redefining lip and/or augmenting lip volume. Only to be administered by appropriately trained healthcare professionals who are qualified or accredited in accordance with national law. Always read and follow the instructions. If you have side effects or concerns speak to your practitioner. Distributed by EnVogue Skin NZ Pty Ltd. EnVogue Skin Pty Ltd. ABN 98 620 276 762. All brands and product names mentioned are trademarks of their respective holders. Copyright © 2023. All rights reserved.

Wegovy® FlexTouch® (semaglutide solution for injection). Available in the following dose forms: 0.25 mg (0.68 mg/mL), 0.5 mg (1.34 mg/mL), 1.0 mg (1.34 mg/mL), 1.7 mg (2.27 mg/mL) and 2.4 mg (3.2 mg/mL). Indication: As an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management (including weight loss and weight maintenance) in adult patients with an initial Body Mass Index (BMI) of ≥30 kg/m2 (obesity) or ≥27 kg/m2 to <30 kg/m2  (overweight) in the presence of at least one weight-related comorbidity; in adolescents ages 12 years and above with initial obesity* and body weight above 60 kg (*obesity (BMI ≥95th percentile) as defined on sex- and age-specific BMI growth charts (CDC.gov) – refer to full datasheet); as an adjunct to standard of care therapy to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with established cardiovascular disease, with a BMI ≥27 kg/m2, and without established Type 1 or Type 2 diabetes. Treatment with Wegovy® should be re-evaluated and discontinued if adolescent patients have not reduced their BMI by at least 5% after 12 weeks on the 2.4 mg or maximum tolerated dose. Dosage and administration: Administered subcutaneously once weekly at any time of day, with or without meals; starting dose 0.25 mg; increase to a maintenance dose of 2.4 mg over a 16-week period at 4 weekly intervals. In case of significant gastrointestinal symptoms, consider delaying dose escalation until symptoms have improved. If patients do not tolerate the 2.4 mg dose, the dose can be decreased to 1.7 mg weekly. Patients should re-escalate to the 2.4 mg dose if tolerated. Doses higher than 2.4 mg are not recommended. Must not be administered intravenously or intramuscularly. Contraindications: Hypersensitivity to semaglutide or any of its excipients. Warnings and precautions: Consider the risk of aspiration during general anaesthesia or deep sedation; dehydration in relation to gastrointestinal side effects in patients with impaired renal function may cause deterioration in renal function; there have been postmarketing reports of acute kidney injury and worsening of chronic renal failure. Inform patients of the characteristic symptoms of acute pancreatitis and discontinue if suspected; do not restart if confirmed. Exercise caution in patients with a history of pancreatitis. Not studied in patients: treated with other products for weight management; with Type 1 diabetes; with congestive heart failure New York Heart Association (NYHA) class IV. Limited experience in patients: aged 85 years or more; with inflammatory bowel disease; with diabetic gastroparesis; with severe renal impairment; with severe hepatic impairment. Must not be used as a substitute for insulin. Should not be used in combination with other GLP-1 products. Treatment in combination with a sulfonylurea or insulin may have an increased risk of hypoglycaemia. The addition of Wegovy® in patients treated with insulin has not been evaluated. Patients with a history of diabetic retinopathy should be monitored for worsening. Not recommended for patients with uncontrolled or unstable diabetic retinopathy. When initiating treatment of semaglutide in patients treated with warfarin or other coumarin derivatives, frequent monitoring of INR is recommended. Pregnancy Category D. Not for use during pregnancy or breast-feeding. Interactions: Semaglutide delays gastric emptying, use with caution in patients receiving oral medicinal products that require rapid gastrointestinal absorption. Undesirable effects: Very Common (≥10%): nausea, vomiting, diarrhoea, constipation, abdominal pain, headache, fatigue. Common (≥1 to <10%): gastritis, gastroesophageal reflux disease, dyspepsia, eructation, flatulence, abdominal distension, dry mouth, dizziness, dysgeusia, dysaesthesia, cholelithiasis, hair loss, injection site reactions; in patients with Type 2 diabetes: hypoglycaemia, diabetic retinopathy. (April 2025)

Novo Nordisk Pharmaceuticals Ltd., G.S.T. 53 960 898. PO Box 51268 Pakuranga, Auckland, New Zealand. Novo Nordisk Medical Information 0800 733 737 www.novonordisk.co.nz. ® Registered trademark of Novo Nordisk A/S 708117. NZ25SEMO00083. TAPS BG5167. Date of preparation: June 2025.